QM
Join List
in this issue of Drug Hunter QM:
New Content
  • Molecules of the Month
  • Practical PK Calculators
  • Webinar: Q2 Highlights
Premium Content
  • MotM Deep Dives
  • Top 10 M&A of 2021
  • Upfront Payments of 2021

This month's edition includes Principia's reversible covalent BTK inhibitors, a single-dose antimalarial, and a brain-penetrant, Ph. II kinase inhibitor for pain, among others.

Thanks to Bryan McKibben, Dennis Koester, Callie Bryan, and Christian Kuttruff for their nominations this month.
Molecules of the Month
Read more about each molecule including what's not in the papers in our Deep Dives, which cover:
  • Where are all of the Molecules of the Month in clinical development?
  • What's known about differentiation from previous molecules?
  • Where did the starting points come from?
  • Industry context, mechanism of action details, and more..
Here's a complimentary preview for e-mail subscribers:
Click to open larger preview.
Premium members can access their slide decks and all ten deep dives by logging in:
Read all Ten Deep Dives
If you’re a chemist, it’s annoying to find a chart in mass units (g/mL) when you care about concentration (M). If you're planning a big animal study, it can be annoying to figure out how much material you should have synthesized.

Together with Dr. Berenger Biannic, we put together three practical PK calculators:
  • Unit conversion from uM to ng/mL and ug/mL (and vice versa)
  • Animal study material planning calculator
  • Human equivalent dose estimator from animal dose
Try the Calculators

We reviewed all of the biotech mergers and acquisitions announced in 2021 and did a deep dive on the list of biotech M&A transactions focused on drug discovery.

In the first two parts of this Premium series, we cover:

  • The top ten overall small or large molecule drug acquisitions of 2021
  • The disclosed upfront payments in 2021's M&A transactions
  • The lead molecules in each acquisition and their structural representations
  • The mechanism of action, stage, and indication of each lead molecule, and more...
Read Part 1: Top 10 Drug Discovery M&A
Read Part 2: Upfront Payments in 2021
upcoming event
Drug Discovery Highlights from Q1 2022
Drug Hunter "Flashtalk" Virtual Event
 
Join us for our premier Drug Hunter webinar in which we cover interesting drug discovery highlights from our articles in the first quarter of 2022, including drug approvals, Molecules of the Month, industry conferences, and other industry developments.

​The format is a Flash Talk, in which we'll quickly cover the key details so you can get caught up over a coffee break, followed by a discussion section in which we'll review questions and letters from audience members.
Register
share Drug Hunter
Know drug hunters that would find this newsletter helpful? Give them your unique referral link (below) to let them sign up too. We'll be raffling off fun things to top referrers, stay tuned~
twitterlinkedinemail
PS: You have referred <<RH_TOTREF>> people so far
more recent content
Here's a recap of other stories recently published on Drug Hunter:
  1. Solid Form Strategies for Increasing Oral Bioavailability
  2. Letters from Drug Hunters #1 – Apr. 2022
  3. New Drug Candidates at AACR New Orleans 2022
  4. Sisunatovir, Oral Ph. II RSV Candidate, to Be Acquired by Pfizer
  5. In Context: First-Time Disclosures of ACS Spring 2022
  6. March 2022 Novel Drug Approvals
  7. 2022 FDA Novel Drug Approvals to Date
  8. Molecules of the Month - February 2022
  9. 2021 Neurology Approvals Deep Dive
  10. Small Molecule of the Year
  11. 2021 Large Molecule Approvals Deep Dive
  12. 2021 First-in-Class Small Molecule Drugs
Get access to Premium for your team at a group rate by contacting us.
featured careers
Vice President,  Medicinal Chemistry
Pin Therapeutics, South San Francisco, CA

Executive Director,  Medicinal Chemistry
Vertex, San Diego, CA

Senior Vice President, Head of Drug Discovery
Genentech/Roche (gRED), South San Francisco, CA
See All Careers
Share an Opportunity
discover together

drughunter.com
Join List
LinkedIn
Twitter
Facebook
Instagram
Copyright © 2022 Drug Hunter Inc., All rights reserved.
You can change how often you receive messages by updating your preferences or remove yourself from this list. Having trouble? Contact us directly.